Emerging Strategies in the Management of Chronic Fibrosing ILD Patients Who Have Contracted COVID-19

Target Audience

This activity is designed to meet the educational needs of pulmonologists, radiologists, pathologists, primary care physicians, physician assistants, registered nurses, nurse practitioners, pharmacists, fellows, residents, and other allied HCPs involved in the management of patients with CF-ILD.

Program Overview

This activity will cover topics on the diagnosis, treatment, and management of patients with chronic fibrosing ILD and CF-ILD patients who have contracted COVID-19.

Learning Objectives

Upon completion of this activity, participants should be better able to:

Evaluate the pathophysiology, prevalence, morbidity, mortality, signs, and symptoms of ILDs with a progressive fibrosing phenotype who have contracted COVID-19
Assess the potential of high-resolution computed tomography (HRCT) and quantitative computed tomography (CT) analysis as the primary tool for the diagnosis of progressive fibrosing phenotype
Cite emerging strategies to increase clinician's awareness of induced severe lung injury and acute respiratory distress syndrome (ARDS) in patients with progressive pulmonary fibrosis recovering from COVID 19